SPOP and MMR/MSI alterations in prostate cancer: relationship with PD-L1, TILs and AR expression
Our analysis identifies SPOP mutations and MMR/MSI status as cofactors in high PD-L1 expression and CD8/TIL presence in PCa, representing potential markers for selecting patients who are more likely to respond immunotherapy or to combined treatment.
Authors
- Francesco Pierconti
- Valeria Zuccalà (ORCID: https://orcid.org/0000-0003-3478-9217)
- Maurizio Martini (ORCID: https://orcid.org/0000-0002-6260-6310)
- Eugenia Guida (ORCID: https://orcid.org/0000-0002-1690-3277)
- Augusto Orlandi (ORCID: https://orcid.org/0000-0001-7202-5854)
- Angelo Totaro
- Vincenzo Fiorentino (ORCID: https://orcid.org/0000-0002-1132-1761)
- Cristina Pizzimenti (ORCID: https://orcid.org/0000-0002-4387-7174)
- Tonia Cenci (ORCID: https://orcid.org/0000-0002-6272-4587)
- Susanna Dolci (ORCID: https://orcid.org/0000-0002-6864-3673)
- Sara Capodimonti (ORCID: https://orcid.org/0000-0003-2760-7593)
- Emanuela Germanà (ORCID: https://orcid.org/0009-0008-1905-8700)
- Gabriele Ricciardi (ORCID: https://orcid.org/0009-0002-1349-0910)
- Guido Fadda
- Vincenzo Ficarra
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Messina (IT)
- University of Rome Tor Vergata (IT)
- Istituto Ortopedico Rizzoli (IT)
- University of the Sacred Heart (JP)
Publication Details
- Journal
- Pathologica
- Published
- 2025-10-01
- DOI
- https://doi.org/10.32074/1591-951x-n979
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52